Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-12-12

FDA Approved: VOLTAREN ARTHRITIS PAIN — Supplemental Application (Haleon US Holdings LLC)

View source ↗

Summary

The FDA approved a supplemental application for Voltaren Arthritis Pain (diclofenac sodium) to expand labeling for arthritis pain management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Voltaren Arthritis Pain (Diclofenac sodium)

Snippet

SUPPL AP for VOLTAREN ARTHRITIS PAIN (DICLOFENAC SODIUM)